logo
Twitter
Discord
Email
logo
Zoetis Inc.

Zoetis Inc.

NYSE•ZTS
CEO: Ms. Kristin C. Peck
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2013-02-01
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
Contact Information
10 Sylvan Way, Parsippany, NJ, 07054, United States
973-822-7000
www.zoetis.com
Market Cap
$53.87B
P/E (TTM)
20.4
82.8
Dividend Yield
1.6%
52W High
$177.40
52W Low
$115.25
52W Range
11%
Rank10
7.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 7.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$2.40B+0.50%
4-Quarter Trend

EPS

$1.63+7.95%
4-Quarter Trend

FCF

$805.00M+2.68%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Growth Strong Operational Nine months revenue grew 2% to $7.08B; operational growth reached 3% driven by price increases and franchise strength.
Net Income Rises Sharply Nine months net income attributable to Zoetis increased 9% to $2.07B, reflecting strong operational leverage and lower restructuring costs.
Diluted EPS Up 11% Diluted EPS for nine months reached $4.65, marking an 11% increase compared to $4.18 reported in the prior year period.
Working Capital Significantly Improved Working capital improved to $4.78B as of September 30, 2025, supported by strong operating cash flow generation and debt management.

Risk Factors

Foreign Exchange Headwinds Persist FX movements negatively impacted reported revenue growth by approximately 1% for the nine months ended September 30, 2025.
Tax Audit Exposure Noted IRS audit proposes additional tax liability of approximately $450M, creating potential material adverse impact on future tax provisions.
Supply Chain Cost Pressures SG&A expenses increased due to higher compensation and operating costs, partially offsetting gross profit improvements in Q3 2025.
Litigation Contingencies Complex Legal and environmental contingencies involve complex judgments; accrued loss estimates may not reflect final outcomes or potential liabilities.

Outlook

New Credit Facility Secured Entered new $1.25B senior unsecured revolving credit facility in August 2025, expiring in December 2027, ensuring liquidity.
Debt Refinancing Completed Issued 2025 Senior Notes to redeem prior notes, managing debt profile; long-term debt increased to $7.07B.
Share Repurchase Authorization Active Board authorized up to $6B repurchase program; $4.5B remains available as of September 30, 2025, for discretionary purchases.
New Accounting Standards Adopted Adopted ASU 2023-09 for income tax disclosures effective January 1, 2025, impacting future annual financial statement disclosures.

Peer Comparison

Revenue (TTM)

Cencora, Inc.COR
$321.33B
+9.3%
The Cigna GroupCI
$268.13B
+15.3%
GSK plcGSK
$32.17B
+2.7%

Gross Margin (Latest Quarter)

Regeneron Pharmaceuticals, Inc.REGN
86.1%
-0.7pp
Alnylam Pharmaceuticals, Inc.ALNY
84.2%
+1.4pp
GSK plcGSK
73.6%
+3.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
GSK$98.84B13.437.4%28.9%
REGN$79.32B17.415.3%6.7%
CI$72.63B11.815.1%21.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.2%
Moderate Growth
4Q Net Income CAGR
7.5%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 12, 2026
|
EPS:$1.40
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 4, 2025|
    Revenue: $2.40B+0.5%
    |
    EPS: $1.63+7.9%
    Meet

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 5, 2025|
    Revenue: $2.46B+4.2%
    |
    EPS: $1.61+17.5%
    Meet

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 6, 2025|
    Revenue: $2.22B+1.4%
    |
    EPS: $1.41+7.6%
    Meet

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 13, 2025|
    Revenue: $9.26B+8.3%
    |
    EPS: $5.47+7.7%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 4, 2024|
    Revenue: $2.39B+11.0%
    |
    EPS: $1.51+17.1%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 6, 2024|
    Revenue: $2.36B+8.3%
    |
    EPS: $1.37-5.5%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 2, 2024|
    Revenue: $2.19B+9.5%
    |
    EPS: $1.31+10.1%
    Meet

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 13, 2024|
    Revenue: $8.54B+5.7%
    |
    EPS: $5.08+12.6%
    Miss